Pharmaceutical PV DIV - FSB
Ended Awarded Last action
- Contract number
- SPE2DU26FEMQE
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $253,265
Award facts
- Contract value 100% obligated
- $253,265.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $253,265.40 by the Defense Logistics Agency on January 5, 2026, with an ultimate completion date of January 6, 2026. This delivery order was issued under the company's single-award Indefinite Delivery Contract (IDC) with a $499.999 billion ceiling established under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which commenced on November 13, 2025, and extends through December 31, 2036. The contract was awarded without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. No subcontractors have been identified in the award documentation.
Under this delivery order, DMS Pharmaceutical Group will supply pharmaceutical products and medical consumables to support Department of Defense healthcare operations. The company's comprehensive product portfolio includes branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, and specialty pharmaceuticals spanning multiple therapeutic categories including oncology treatments, immunosuppressants, emergency medications, surgical products, and routine pharmaceuticals. The PPV-G GEN V program represents a $30.3 billion government-wide acquisition strategy designed to enable the Defense Logistics Agency to efficiently procure diverse pharmaceutical requirements for military healthcare facilities worldwide through multiple regional prime vendor contractors, with DMS Pharmaceutical Group positioned as one of these critical suppliers to sustain recurring medical supply needs across the Department of Defense.
Quick answers
Who was awarded contract SPE2DU26FEMQE?
SPE2DU26FEMQE was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DU26FEMQE worth?
The government has obligated $253,265 on SPE2DU26FEMQE.
Is contract SPE2DU26FEMQE an order under another contract?
Yes. SPE2DU26FEMQE is a delivery order under SPE2DU25D9517, an indefinite delivery contract.
Was contract SPE2DU26FEMQE competed?
The extent of competition for SPE2DU26FEMQE was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award